The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy

Journal of Inflammation Research, Journal Year: 2025, Volume and Issue: Volume 18, P. 4335 - 4357

Published: March 1, 2025

Monoclonal antibodies (mAbs) have transformed cancer treatment by providing highly targeted and effective therapies that specifically attack cells, thus reducing the likelihood of adverse events (AEs) in patients. mAbs exert their action through various mechanisms, such as receptor blockade, antibody-dependent cellular cytotoxicity (ADCC), complement-dependent (CDC), inhibition immune checkpoints (eg, PD-1, PD-L1, CTLA-4). These led to significant improvements several cancers, including HER2-positive breast cancer, non-small cell lung (NSCLC), melanoma. The efficacy mAb therapy is influenced intrinsic extrinsic factors, environmental exposures, psychosocial infection status, ways life, tumor microenvironment (TME), all which can impact responses outcomes. Notably, therapeutic benefits are often accompanied immune-related AEs (irAEs), vary from mild severe affect multiple organ systems. dual nature mAbs-stimulating antitumor while also inducing side effects-presents a notable challenge clinical practice. This review highlights importance proactive strategies for managing irAEs, early detection, corticosteroid use, immunosuppressive treatments, urgent need reliable predictive biomarkers improve Advancements prevention, prediction, management irAEs essential enhance safety effectiveness mAb-based therapies, ultimately aiming patient

Language: Английский

Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data

Antibodies, Journal Year: 2024, Volume and Issue: 13(3), P. 56 - 56

Published: July 15, 2024

The advancement of immuno-oncology has brought about a significant shift in cancer treatment methods, with antibody-based immune checkpoint inhibitors like atezolizumab leading the way this regard. However, use blockade can result immune-related adverse events due to increased T-cell activity. full spectrum these is not yet completely understood. In study, United States FDA Adverse Event Reporting System (FAERS) was utilized investigate linked atezolizumab. study identified forty-nine that affected multiple organ systems, including cardiovascular, respiratory, hematologic, hepatic, renal, gastrointestinal, neurologic, musculoskeletal, dermatologic, endocrine, and systemic disorders. strongest signals for relative risk occurred immune-mediated encephalitis (RR = 93.443), autoimmune myocarditis 56.641), hepatitis 49.062), nephritis 40.947), arthritis 39.382). Despite morbidity associated events, emerging evidence suggests potential associations improved survival outcomes. Overall, report sheds light on widespread cause mortality patients being treated brings attention them clinicians treating patients.

Language: Английский